292 related articles for article (PubMed ID: 27785927)
1. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.
Pardanani A; Gotlib J; Roberts AW; Wadleigh M; Sirhan S; Kawashima J; Maltzman JA; Shao L; Gupta V; Tefferi A
Leukemia; 2018 Apr; 32(4):1035-1038. PubMed ID: 29263442
[No Abstract] [Full Text] [Related]
3. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Chifotides HT; Bose P; Verstovsek S
J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
[TBL] [Abstract][Full Text] [Related]
4. Momelotinib for the treatment of myelofibrosis with anemia.
Tremblay D; Mesa R
Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
[TBL] [Abstract][Full Text] [Related]
5. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
[TBL] [Abstract][Full Text] [Related]
6. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
Abdelrahman RA; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Pardanani A; Tefferi A
Br J Haematol; 2015 Apr; 169(1):77-80. PubMed ID: 25511866
[TBL] [Abstract][Full Text] [Related]
7. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
8. Momelotinib for the treatment of myelofibrosis.
Xu L; Feng J; Gao G; Tang H
Expert Opin Pharmacother; 2019 Nov; 20(16):1943-1951. PubMed ID: 31450973
[No Abstract] [Full Text] [Related]
9. Momelotinib: First Approval.
Keam SJ
Drugs; 2023 Dec; 83(18):1709-1715. PubMed ID: 37989928
[TBL] [Abstract][Full Text] [Related]
10. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
11. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
12. Investigational Janus kinase inhibitors in development for myelofibrosis.
Bose P; Abou Zahr A; Verstovsek S
Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
[TBL] [Abstract][Full Text] [Related]
13. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
14. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
16. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
17. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
Verstovsek S; Courby S; Griesshammer M; Mesa RA; Brachmann CB; Kawashima J; Maltzman JD; Shao L; Xin Y; Huang D; Bajel A
Leuk Res; 2017 Sep; 60():11-17. PubMed ID: 28622623
[TBL] [Abstract][Full Text] [Related]
19. Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
Mascarenhas J
Leuk Lymphoma; 2015; 56(9):2493-7. PubMed ID: 25586607
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
